Supernus commercial portfolio of products treating neurological and psychiatric conditions including ADHD, epilepsy, Parkinson's disease, and migraine.
Supernus develops and commercializes products for neurological and psychiatric conditions, with therapeutic areas spanning epilepsy, migraine, Parkinson's disease, attention deficit/hyperactivity disorder (ADHD), and postpartum depression. Its commercial portfolio includes Qelbree for ADHD, Onapgo and Apokyn for Parkinson's disease, and Gocovri for dyskinesia in patients with Parkinson's disease.
Additional marketed products include Zurzuvae for postpartum depression developed in collaboration with Biogen, Myobloc, Oxtellar XR and Trokendi XR for epilepsy, and Xadago as an adjunct to levodopa/carbidopa treatment in Parkinson's disease. Supernus presents each commercial product on its commercial-products page with a link to the therapy's dedicated website.
| Attribute | Neurological and Psychiatric Products | Exeltis — Central Nervous System | |
|---|---|---|---|
| Provider | |  | |
| Founded | 2005 | 2003 | |
| Sells To | Enterprise | — | |
| Pricing Model | Recurring | — | |
| Ownership | Public | — |
Provider
Founded 2005
Sells To Enterprise
Pricing Model Recurring
Ownership Public
Provider
Founded 2003
Sells To —
Pricing Model —
Ownership —
Lundbeck's portfolio of registered therapies for neurological and psychiatric brain diseases, marketed across more than 80 countries.
Central nervous system portfolio covering antidepressants, anticonvulsants, migraine, ADHD, and neurodegeneration medicines.
UCBUCB's solutions line addressing neurological and autoimmune conditions, delivered through its global biopharmaceutical portfolio.
Lundbeck's portfolio of registered therapies for neurological and psychiatric brain diseases, marketed across more than 80 countries.
Central nervous system portfolio covering antidepressants, anticonvulsants, migraine, ADHD, and neurodegeneration medicines.
UCB's solutions line addressing neurological and autoimmune conditions, delivered through its global biopharmaceutical portfolio.
UCB